Leading Product Revenue

August 7. 2024

(¥ million)

Brand name Active Ingredient Indications Launch Date Sales 2022
(IFRS)
Sales 2023
(IFRS)
Sales 2024 (IFRS)
Apr-Jun Apr-Sep
(estimated)
Annual
(estimated)
Viltepso       14,341 17,530 5,450 10,300 20,600
(Japan) viltolarsen Duchenne muscular
dystrophy
Japan May-2020
U.S. Aug-2020
(4,139) (4,407) 1,175 2,300 4,600
(U.S.)       (10,201) (13,123) 4,275 8,000 16,000
Uptravi selexipag pulmonary arterial hypertension/
chronic thromboembolic pulmonary hypertension
Nov-2016/
Aug-2021
10,543 12,918 3,855 7,600 15,400
Vidaza azacitidine myelodysplastic syndrome/
acute myeloid leukemia
Mar-2011/
Mar-2021
15,951 10,383 1,462 2,600 4,800
Gazyva obinutuzumab CD20-positive follicular lymphoma/
CD20-positive chronic lymphocytic leukemia
Aug-2018/
Dec-2022
4,904 4,695 1,254 2,500 5,100
Tramal, Onetram tramadol hydrochloride cancer pain, chronic pain Sep-2010 5,358 3,927 778 1,400 2,700
Defitelio defibrotide sodium sinusoidal obstruction syndrome Sep-2019 2,524 2,221 709 1,100 2,300
Cialis tadalafil erectile dysfunction Jul-2009 2,938 2,499 647 1,400 2,700
Zalutia tadalafil urinary disorder caused by benign prostatic hyperplasia Apr-2014 2,826 2,256 493 850 1,600
Adcirca tadalafil pulmonary arterial hypertension Dec-2009 2,649 2,255 480 900 1,700
Erizas dexamethasone cipecilate allergic rhinitis Dec-2009 2,640 2,284 281 700 2,100
Profit in co-promotion 9,520 8,658 2,461 4,550 9,100
Revenues from the licensing of industrial property rights 30,714 40,304 10,779 21,000 42,100
Pharmaceuticals 121,988 125,105 33,738 65,300 132,500
Functional Food 22,187 23,150 5,393 10,500 21,500
Revenue 144,175 148,255 39,131 75,800 154,000